Holen Sie sich die Stockscreener-App
34.64
1.84%
-0.6596
Indivior Pharmaceuticals Inc Aktie (INDV) Neueste Nachrichten
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan - Yahoo Finance
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Yahoo Finance
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks? - Yahoo Finance
Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.3% -- GF Value Says Still Overvalued - GuruFocus
Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal - Ad-hoc-news.de
Indivior stock edges higher as options activity and analyst targets point to further upside - Ad-hoc-news.de
Layoff Tracker: Kolon TissueGene cuts 37 US staffers after Phase 3 fail - BioSpace
Indivior Q2 2026 Earnings Call: Complete Transcript - Sahm
Indivior (INDV) Gains 2.07% to $39.01 as Opioid Addiction Treatment Demand Lifts Pharma StockBreakout Trade - vinanet.vn
Indivior Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:INDV - TradingView
Is Indivior Pharmaceuticals (INDV) Below Fair Value Despite A 194% Return? - Sahm
Indivior Pharmaceuticals, Inc. Revenue Breakdown – FWB:E7P - TradingView
Oaktree trims Indivior (INDV) holdings, files Schedule 13D exit amendment - Stock Titan
Indivior Pharmaceuticals, Inc. (INDV) Options Chain - Yahoo! Finance Canada
Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis
Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - Yahoo Finance
Indivior Plc (INDV) News, Articles, Events & Latest Updates - Stocktwits
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc. - simplywall.st
Indivior Pharmaceuticals, Inc. (INDV) stock price, news, quote and history - uk.finance.yahoo.com
Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Exploring a 27% Potential Upside Amid Strong Revenue Growth - DirectorsTalk Interviews
Hennion & Walsh Asset Management Inc. Invests $14.78 Million in Indivior PLC $INDV - MarketBeat
Assenagon Asset Management S.A. Buys Shares of 1,540,928 Indivior PLC $INDV - MarketBeat
Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc.,M&A CallSlideshow - Seeking Alpha
Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? - tradingview.com
Rockville-Based Supernus and Indivior Agree to Merge, Creating a $2.2B CNS Powerhouse Headquartered in Maryland - BioBuzz
Indivior Pharmaceuticals Inc (INDV) Shares Surge 6.1% -- What GF Score of 75 Tells Investors - GuruFocus
Indivior Pharmaceuticals (INDV) CAO purchases 1,500 common shares - Stock Titan
Supernus And Indivior To Merge And Create $2.2 Billion CNS Biopharmaceutical Company - Pulse 2.0
Earnings call transcript: Supernus jumps on Indivior merger in Q2 2026 - Investing.com Nigeria
Supernus Pharmaceuticals Falls as Investors Weigh Newly Announced Indivior Merger Terms - moomoo.com
Supernus Pharmaceuticals falls as investors weigh newly announced Indivior merger terms - Quiver Quantitative
Supernus and Indivior to Merge, Creating Diversified CNS Biopharma Company - Contract Pharma
$1.8bn merger unites Supernus and Indivior in CNS therapeutics play - BioXconomy
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook - Yahoo Finance
Indivior Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Supernus and Indivior merge to create scaled, CNS-focused entity - Yahoo Finance
Raleigh drug factory part of $2B merger - The Business Journals
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Analyst Consensus Points to 36% Upside Potential - DirectorsTalk Interviews
Supernus, Indivior merge to strengthen neuroscience drug portfolio - 1470 & 100.3 WMBD
Indivior and Supernus (SUPN) outline tax-free all-stock CNS merger of equals - stocktitan.net
Supernus and Indivior to merge, forming $2.2B CNS drug company - Dealroom
Supernus Pharmaceuticals (SUPN) outlines investor and employee outreach on Indivior merger of equals - Stock Titan
Indivior Pharmaceuticals, Inc. 2026: Revenue $343M, EPS $0.98— 10-Q Summary - TradingView
Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company - MedCity News
Indivior Falls as Investors Reposition Ahead of Second-Quarter Results - Quiver Quantitative
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue - Benzinga
Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook - Yahoo Finance
Supernus Pharmaceuticals (SUPN) details Indivior merger call and planned S-4 proxy filings - Stock Titan
Indivior Pharmaceuticals Inc. R (E7P.MU) Q2 FY2026 & Merger earnings call transcript - Yahoo Finance
CNS-focused Supernus and Indivior agree merger terms - pharmaphorum
Supernus and Indivior agree to merge in all-stock deal - Investing.com
Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates - finance.yahoo.com
Weekly Recap: All-stock merger with Supernus and 2026 SUBLOCADE guidance - TradingView
Indivior stock soars 9% on strong earnings beat and raised guidance - Investing.com South Africa
Weekly Recap: Indivior merger, 1.5401 exchange and Q2 revenue, guide up - TradingView
Supernus Pharmaceuticals (SUPN) agrees merger-of-equals with Indivior and $1B special dividend - Stock Titan
Indivior (INDV) Q2 2026: EPS Beats by 25%, SUBLOCADE Sets Record - 24/7 Wall St.
Supernus and Indivior agree to merge in all-stock deal By Investing.com - Investing.com Nigeria
Indivior Pharmaceuticals Q2 Non-GAAP Earnings, Revenue Rise; 2026 Sales Outlook Upgraded - Yahoo Finance
Indivior Reports Record Q2 2026 Revenue, SUBLOCADE Sales and Profitability; Raises Full-Year Guidance Amid Supernus Merger Announcement - Quiver Quantitative
Indivior Pharmaceuticals beats Q2 revenue on Sublocade growth, raises FY guidance - TradingView
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance - GlobeNewswire
Press Release: Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader With Significant Scale - Moomoo
Indivior Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Indivior PLC (INDV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
2.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):